Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer [0.03%]
TET2(Tet methylcytosine dioxygenase 2)缺乏引起非小细胞肺癌的EGFR-TKI(酪氨酸激酶抑制剂)耐药性
Jian Zhang,Kejia Zhao,Wenjing Zhou et al.
Jian Zhang et al.
Despite epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have shown remarkable efficacy in patients with EGFR-mutant non-small cell lung cancer (NSCLC), acquired resistance inevitably develops, limiting clinical effi...
Alpha5 nicotine acetylcholine receptor subunit promotes intrahepatic cholangiocarcinoma metastasis [0.03%]
α5尼古丁乙酰胆碱受体亚单位促进肝内胆管癌转移
Yan Fu,Keyu Shen,Hao Wang et al.
Yan Fu et al.
Neurotransmitter-initiated signaling pathway were reported to play an important role in regulating the malignant phenotype of tumor cells. Cancer cells could exhibit a "neural addiction" property and build up local nerve networks to achieve...
Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer [0.03%]
靶向肉碱棕榈酰转移酶1A(CPT1A)诱导铁死亡并协同治疗肺癌免疫疗法
Lei Ma,Chong Chen,Chunxing Zhao et al.
Lei Ma et al.
Despite the successful application of immune checkpoint therapy, no response or recurrence is typical in lung cancer. Cancer stem cells (CSCs) have been identified as a crucial player in immunotherapy-related resistance. Ferroptosis, a form...
Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies [0.03%]
癌症中的铁死亡：从分子机制到治疗策略
Qian Zhou,Yu Meng,Daishi Li et al.
Qian Zhou et al.
Ferroptosis is a non-apoptotic form of regulated cell death characterized by the lethal accumulation of iron-dependent membrane-localized lipid peroxides. It acts as an innate tumor suppressor mechanism and participates in the biological pr...
Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma [0.03%]
抗代谢药物聚乙二醇天冬酰胺酶联合PD-1抗体替雷利尤单抗用于晚期NK/T细胞淋巴瘤的一线治疗
Jie Xiong,Shu Cheng,Xiao Gao et al.
Jie Xiong et al.
Natural killer T cell lymphoma (NKTCL) is highly aggressive, with advanced stage patients poorly responding to intensive chemotherapy. To explore effective and safe treatment for newly diagnosed advanced stage NKTCL, we conducted a phase II...
Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1 [0.03%]
以宿主cathepsin l和calpain-1为靶点的广谱冠状病毒抑制剂的结构辅助设计
Xiong Xie,Qiaoshuai Lan,Jinyi Zhao et al.
Xiong Xie et al.
Respiratory disease caused by coronavirus infection remains a global health crisis. Although several SARS-CoV-2-specific vaccines and direct-acting antivirals are available, their efficacy on emerging coronaviruses in the future, including ...
New clinical trial design in precision medicine: discovery, development and direction [0.03%]
精准医学中新临床试验设计：发现、发展和方向
Xiao-Peng Duan,Bao-Dong Qin,Xiao-Dong Jiao et al.
Xiao-Peng Duan et al.
In the era of precision medicine, it has been increasingly recognized that individuals with a certain disease are complex and different from each other. Due to the underestimation of the significant heterogeneity across participants in trad...
Suppression of ITPKB degradation by Trim25 confers TMZ resistance in glioblastoma through ROS homeostasis [0.03%]
Trim25通过ROS平衡抑制ITPKB降解从而赋予胶质母细胞瘤TMZ耐药性
Yuanliang Yan,Shangjun Zhou,Xi Chen et al.
Yuanliang Yan et al.
Temozolomide (TMZ) represents a standard-of-care chemotherapeutic agent in glioblastoma (GBM). However, the development of drug resistance constitutes a significant hurdle in the treatment of malignant glioma. Although specific innovative a...
NF-κB in biology and targeted therapy: new insights and translational implications [0.03%]
NF-κB在生物学及针对性治疗中的新见解与应用前景
Qing Guo,Yizi Jin,Xinyu Chen et al.
Qing Guo et al.
NF-κB signaling has been discovered for nearly 40 years. Initially, NF-κB signaling was identified as a pivotal pathway in mediating inflammatory responses. However, with extensive and in-depth investigations, researchers have discovered ...
Eliciting CD4-mimicking broadly neutralizing antibodies: new avenues towards the rational design of an HIV vaccine [0.03%]
诱导CD4模仿的广谱中和抗体：艾滋病疫苗合理设计的新途径
Frauke Muecksch,Oliver T Fackler
Frauke Muecksch